Continuation of OnabotulinumtoxinA treatment for chronic migraine based on initial expectations


  • The expectation of benefit and procedural discomfort (PD) with onabotulinumtoxinA (BTX) treatment for chronic migraine (CM) does not correlate with continuation of therapy in clinical care.

Why this matters ?

    While BTX is a widely available treatment for CM, it has previously been unclear if expectations for treatment efficacy impact the success of treatment.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.